Lowering blood pressure to 135/85 mm Hg using nonpharmacologic approaches and combination drug therapy, particularly RAAS blockers, is recommended for patients with diabetes.
In patients with diabetes, lowering blood pressure to 135/85 mm Hg using nonpharmacologic and pharmacologic therapies, primarily RAAS blockers, is recommended to reduce cardiorenal risk.
Hypertension is a major modifiable risk factor for cardiovascular morbidity and mortality in patients with diabetes. Lowering blood pressure (BP) to 135/85 mm Hg is the main goal of treatment. A nonpharmcologic approach is recommended in all patients. If BP levels remain above the target despite nonpharmacologic treatment, drug therapy should be initiated. Blockers of the renin-angiotensin-aldosterone system (RAAS) represent the cornerstone of the antihypertensive drug arsenal; however, in most patients, combination therapy is required. For many patients, a combination of RAAS blocker and calcium antagonist is the combination preferred by the treating physician. Often three or even four drugs are needed. Treatment should be individualized according to concomitant risk factors and diseases and depending on the age and hemodynamic and laboratory parameters of the patient. In order to maximally reduce cardio renal risk, control of lipid and glycemic levels should also be ensured.
Grossman et al. (Thu,) conducted a review in Hypertension in patients with diabetes. Blood pressure management (nonpharmacologic and pharmacologic) was evaluated. Lowering blood pressure to 135/85 mm Hg using nonpharmacologic approaches and combination drug therapy, particularly RAAS blockers, is recommended for patients with diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: